Article History
Accepted: 4 October 2022
First Online: 9 November 2022
Competing interests
: D.K. receives consulting fees from Acceleron, Actelion, Amgen, Boehringer Ingelheim, Chemomab, CSL Behring, Genentech/Roche, Horizon, Mitsubishi Tanabe Pharma, Paracrine Cell Therapy, Prometheus and Theraly. The other authors declare no competing interests.